Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-11-20
2007-11-20
Haddad, Maher M. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100
Reexamination Certificate
active
10292869
ABSTRACT:
A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
REFERENCES:
patent: 4490473 (1984-12-01), Brunhouse
patent: 4752601 (1988-06-01), Hahn
patent: 5204244 (1993-04-01), Fell et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5419904 (1995-05-01), Irie
patent: 5576184 (1996-11-01), Better et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5698449 (1997-12-01), Baumann et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward
patent: 6491916 (2002-12-01), Bluestone et al.
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6676927 (2004-01-01), Ravetch
patent: 6706265 (2004-03-01), Bolt et al.
patent: 6737056 (2004-05-01), Presta
patent: 6821505 (2004-11-01), Ward
patent: 2001/0036459 (2001-11-01), Ravetch
patent: 2002/0098193 (2002-07-01), Ward
patent: 2003/0158389 (2003-08-01), Idusogie et al.
patent: 2003/0166868 (2003-09-01), Presta et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0191244 (2004-09-01), Presta
patent: 2004/0228856 (2004-11-01), Presta
patent: 2005/0118174 (2005-06-01), Presta
patent: 2005/0233382 (2005-10-01), Presta
patent: WO 88/07089 (1988-09-01), None
patent: WO 93/22332 (1993-11-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/44362 (1997-11-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/52975 (1998-11-01), None
patent: WO 99/43713 (1999-09-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 02/060919 (2002-08-01), None
Idusogie et al. Engineered antibody with increased activity to recruit complement. The Journal of Immunology, 2001, 166:25712575.
Bolland et al., “SHIP modulates immune receptor responses by regulating membrane association of Btk”Immunity8(4):509-516 (Apr. 1998).
Burton et al., “Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI)”Molecular Immunology25(11):1175-1181 (1998).
Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy”Nature337:525-531 (1989).
Chappel et al., “Identification of Secondary FcγRI Binding Site within a Genetically Engineered Human IgG Antibody”Journal of Biological Chemistry268:25124-25131 (1993).
Clynes and Ravetch., “Cytotoxic antibodies trigger inflammation through Fc receptors”Immunity3(1):21-26 (Jul. 1995).
Clynes et al., “Fc Receptors Are Required in Passive and Active Immunity to Melanoma.”Proc. Natl. Acad. Sci. USA95(2):652-656 (Jan. 20, 1998).
Clynes et al., “Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors”Journal of Experimental Medicine189(1):179-185 (Jan. 4, 1999).
Clynes et al., “Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis”Science279(5353):1052-1054 (Feb. 13, 1998).
Guddat et al., “Three-dimensional structure of a human immunoglobulin with a hinge deletion”PNAS(USA) 90:4271-4275 (1993).
Haagen et al., “Interaction of Human Monocyte Fcγ Receptors with Rat IgG2b: A New Indicator for the PcγRIIa (R-H131) Polymorphism”J. Immunol. 154:1852-1860 (1995).
Harris et al., “Crystallographic Structure of an Intact IgG1 Monoclonal Antibody”Journal of Molecular Biology275:861-872 (1998).
Harris et al., “Refined Structure of an Intact IgG2a Monoclonal Antibody”Biochemistry36:1581-1597 (1997).
Hatta et al., “Association of Fcγ Receptor IIIB, But Not of Fcγ Receptor IIA and IIIA, Polymorphisms with SystemicLupus erythematosusin Japanese.”Genes and Immunity1:53-60 (1999).
Heiken et al., “T lymphocyte development in the absence of FcΣ receptor Iγ subunit: analysis of thymic-dependent and independent αβ and γδ pathways”European Journal of Immunology26(8):1935-1943 (Aug. 1996).
Hulett et al., “Chimeric Fc Receptors Identify Functional Domains of the Murine High Affinity Receptors for IgG”J. Immunol. 147:1863-1868 (1991).
Kabat et al.Sequences of Proteins of Immunological Interest(Table of Contents, Introduction and Constant Region Sequences sections), 5th edition, Bethesda, MD:NIH vol. 1:iii-xcvi and 647-723 (1991).
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo”Nature362:841-844 (1993).
Kim et al., “Mapping the site of human IgG for binding of the MHC class I-related receptor. FcRn”European Journal of Immunology29(9):2819-2825 (Sep. 1999).
Kim et al., “The Vascular Endothelial. Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies”Growth Factors7(1):53-64 (1992).
Koene et al., “FcγRIIIa-158V/F Polymorphism Influences the Binding of the IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype”Blood90(3):1109-1114 (1997).
Lehrnbecher et al., “Variant genotypes of FcγRIIIA influence the development of Kaposi's sarcoma in HIV-infected men”Blood95(7):2386-2390 (2000).
Li et al., “Reconstitution of human FcγRIII cell type specificity in transgenic mice”Journal of Experimental Medicine183(3):1259-1263 (Mar. 1, 1996).
Lifely et al., “Glycosylation and Biological Activity of CAMPATH-1H Expressed in Different Cell Lines and Grown Under Different Culture Conditions.”Glycobiology5(8):813-822 (Dec. 1995).
Lucas et al., “High-Level Production of Recombinant Proteins in CHO Cells Using a Dicistronic DHFR Intron Expression Vector.”Nucleic Acids Research24(9):1774-1779 (1996).
Lund et al., “Multiple Interactions of the IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fcγ Receptor I and Influence the Synthesis of Its Oligosaccharide Chains”J. Immunol. 157:4963-4969 (1996).
Lund et al., “Oligosaccharide-protein interactions in IgG can modulate recognition by Fcγ receptors”FASEB Journal9:115-119 (1995).
Martin et al., “Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding”Molecular Cell7(4):867-877 (Apr. 2001).
Maxwell et al., “Crystal structure of the human leukocyte Fc receptor, FcγRIIa”Nature Structural Biology6(5):437-442 (May 1999).
Meng et al., “Green fluorescent protein as a second selectable markerfor selection of high producing clones from transfected CHO cells”Gene242:201-207 (2000).
Miller et al., “A Novel Role for the Fc Receptor γ Subunit: Enhancement of the FcγR Ligand Affinity”Journal of Experimental Medicine183:2227-2233 (1996).
Nieto et al., “Involvement of the Fcγ receptor IIIA genotypes in susceptibility
Idusogie Esohe Ekinaduese
Mulkerrin Michael George
Presta Leonard G.
Crowder Chun
Genentech Inc.
Haddad Maher M.
Lee Wendy M.
LandOfFree
Polypeptide variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876808